NASDAQ:IFRX InflaRx Q3 2023 Earnings Report $0.85 +0.04 (+4.42%) Closing price 04:00 PM EasternExtended Trading$0.85 0.00 (-0.47%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast InflaRx EPS ResultsActual EPS-$0.14Consensus EPS -$0.29Beat/MissBeat by +$0.15One Year Ago EPSN/AInflaRx Revenue ResultsActual Revenue$0.07 millionExpected Revenue$1.84 millionBeat/MissMissed by -$1.77 millionYoY Revenue GrowthN/AInflaRx Announcement DetailsQuarterQ3 2023Date11/1/2023TimeN/AConference Call DateWednesday, November 1, 2023Conference Call Time6:00AM ETUpcoming EarningsInflaRx's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) InflaRx Earnings HeadlinesInflaRx Announces Receipt of Nasdaq Deficiency Notice ... - MorningstarJuly 12, 2025 | morningstar.comMInflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum ...July 12, 2025 | seekingalpha.comThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important updates you'll ever see. A new initiative, linked to President Trump's Executive Order #14196, has the potential to do more than just protect Social Security from collapse... According to renowned investor Louis Navellier, it could increase benefits by as much as 400%.July 16 at 2:00 AM | InvestorPlace (Ad)InflaRx N.V.: InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementJuly 12, 2025 | finanznachrichten.deInflaRx N.V. Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price RequirementJuly 11, 2025 | quiverquant.comQInflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementJuly 11, 2025 | globenewswire.comSee More InflaRx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like InflaRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InflaRx and other key companies, straight to your email. Email Address About InflaRxInflaRx (NASDAQ:IFRX) NV is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic antibodies targeting components of the innate immune system. The company’s lead program is vilobelimab (IFX-1), a monoclonal antibody that selectively inhibits the complement factor C5a, a potent driver of inflammation. InflaRx is advancing vilobelimab in multiple indications, including hidradenitis suppurativa, paroxysmal nocturnal hemoglobinuria and other rare and severe inflammatory diseases, with both ongoing and planned clinical trials. Founded in 2007 and headquartered in Jena, Germany, InflaRx maintains operational offices in the United States to support its North American development and regulatory activities. The company has established strategic collaborations for manufacturing and clinical research in Europe and North America, ensuring access to state-of-the-art facilities and patient populations. InflaRx completed its initial public offering on the NASDAQ stock exchange in 2019 to accelerate its pipeline advancement and expand global clinical programs. Under the leadership of Chief Executive Officer Jan Schmidt, InflaRx is led by a management team with extensive experience in immunology, drug development and regulatory affairs. The company’s board and scientific advisory group include industry veterans from biotechnology and pharmaceutical backgrounds who guide strategy and clinical program design. InflaRx remains committed to translating its complement-modulating platform into novel therapies that address unmet needs in inflammatory and autoimmune diseases worldwide.Written by Jeffrey Neal JohnsonView InflaRx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong Upcoming Earnings Cintas (7/17/2025)Interactive Brokers Group (7/17/2025)Netflix (7/17/2025)PepsiCo (7/17/2025)Abbott Laboratories (7/17/2025)Elevance Health (7/17/2025)GE Aerospace (7/17/2025)American Noble Gas (7/17/2025)Marsh & McLennan Companies (7/17/2025)Novartis (7/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
